Irrespective of whether apoC-III is pro- or antiapoptotic, the currently available insights indicate that this apolipoprotein has the potential to impact adversely on glycaemic control in patients with T1D and T2D by reducing β-cell function. The gene discussed is APOC3; the disease is type 2 diabetes mellitus.